Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Perspective Therapeutics (NYSEAMERICAN:CATX) released its quarterly earnings data on Monday. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04, FiscalAI reports. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX traded up $0.12 during mid-day trading on Monday, hitting $3.88. 1,133,459 shares of the company traded hands, compared to its average volume of 2,837,001. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17. The stock’s fifty day moving average price is $4.56 and its 200-day moving average price is $3.58. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Piper Sandler assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target for the company. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BTIG Research reiterated a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. Finally, B. Riley Financial lifted their price objective on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $12.63.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. UBS Group AG increased its holdings in Perspective Therapeutics by 72.0% in the 3rd quarter. UBS Group AG now owns 641,143 shares of the company’s stock worth $2,199,000 after acquiring an additional 268,433 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Perspective Therapeutics by 227.1% during the second quarter. BNP Paribas Financial Markets now owns 242,610 shares of the company’s stock valued at $835,000 after purchasing an additional 168,448 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Perspective Therapeutics by 7.9% in the fourth quarter. Federated Hermes Inc. now owns 213,759 shares of the company’s stock worth $588,000 after purchasing an additional 15,568 shares during the period. ADAR1 Capital Management LLC bought a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $262,000. Finally, Graham Capital Management L.P. increased its stake in shares of Perspective Therapeutics by 76.8% in the fourth quarter. Graham Capital Management L.P. now owns 80,193 shares of the company’s stock worth $221,000 after purchasing an additional 34,836 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.